Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CHKA | P35790 | 3/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30059168 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2CHKAALDH1A1KDM4ETDP1 | |
| SCHEMBL546902 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2CHKAALDH1A1KDM4ETDP1 | |
| SCHEMBL5525074 | 0.87 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1KDM4ETDP1POLB | |
| SCHEMBL571956 | 0.86 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1KDM4ETDP1POLB | |
| SCHEMBL2952071 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL6609562 | 0.83 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1KDM4ETDP1LMNA | |
| SCHEMBL3103670 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2CHKAALDH1A1KDM4ELMNA | |
| SCHEMBL29710198 | 0.83 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1KDM4ETDP1LMNA | |
| SCHEMBL3117941 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2CHKAHTR6ALDH1A1KDM4E | |
| SCHEMBL28088851 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2CHKAALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| CN-117597346-A | NEK7 inhibitors | 哈利亚治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236954-B2 | Processes for preparing benzimidazole thiophenes | GLAXOSMITHKLINE LLC (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2170871-A2 | PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES | GlaxoSmithKline LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009154645-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| WO-2009002916-A2 | PROCESSES FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | TUBB3, TUBB6, TUBB | SMN1; SMN2 815/4885CHKA 604/4885HTR6 1756/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | SMN1; SMN2 1161/4885CHKA 3829/4885HTR6 2251/4885 |
| US-20100256376-A1 | Processes For Preparing Benzimidazole Thiophenes | TPMT, TBKBP1, TYMP | SMN1; SMN2 1376/4885CHKA 2237/4885HTR6 347/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SMN1; SMN2 3123/4885CHKA 793/4885HTR6 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.